As CEO of 3Sixty Public Affairs, Bill Dempster develops and implements high-impact government relations, policy and business strategies for clients in the health and life sciences sector. For over a decade, Bill has drawn on deep business, legal and government experience to help clients find mutually beneficial solutions to complex regulatory, reimbursement and policy problems. Bill has previously worked for Pfizer Canada, a Member of Parliament, the United Nations and major Canadian law firms. He is fluently bilingual and has degrees in history (King’s College, University of Western Ontario), law (Queen’s University), and a Masters of Arts in international affairs (Norman Paterson School of International Affairs, Carleton University). Bill was called to the Bar of Ontario in 2002.
Agenda: Day 1 Oct 5, 2020
Panel Discussion: THE ROAD TO ADVANCED THERAPEUTICS
Assessing the State of Play: Are Gene Therapies the Next Big Game Changers?
Although still considered by some an experimental technique, gene therapy, which focuses on the genetic modification of cells, is poised to become much more prevalent. Researchers are constantly unveiling new approaches to gene therapy. Inform your development pipeline with an in-depth understanding of these strategies, including:
- Replacing a mutated disease-causing gene with a healthy copy of the gene
- Inactivating, or “knocking out,” a mutated gene that is functioning improperly
- Introducing a new gene into the body to help fight a disease
Equip your team with actionable insights in your development of efficacious gene therapy products
Agenda: Day 2 Oct 6, 2020